

Corrigendum

Corrigendum to ‘Suplatast tosilate, a new type of antiallergic agent, prevents the expression of airway hyperresponsiveness in guinea pigs’ [Eur. J. Pharmacol. 318 (1996) 447–454]¹

Hajime Taniguchi^a, Michinori Togawa^a, Katsuo Ohwada^b, Mamoru Kiniwa^{a,*},
Naosuke Matsuura^a, Hiroichi Nagai^c, Akihide Koda^c

^a Immunological Research Laboratory, Hanno Research Center, Taiho Pharmaceutical Co., Ltd., 1-27 Misugidai, Hanno, Saitama 357, Japan

^b Pharmacology Research Laboratory, Taiho Pharmaceutical Co., Ltd., Kawauchi-cho, Tokushima 771-01, Japan

^c Department of Pharmacology, Gifu Pharmaceutical University, Gifu 502, Japan

Received 16 August 1996; revised 3 October 1996; accepted 8 October 1996

Keywords: Suplatast tosilate; Airway inflammation; Airway hyperresponsiveness; Eosinophil; Lymphocyte; T cell

In the above-mentioned article, page 449, legend to Fig. 1, line 4 should read: ‘... inhaled ovalbumin. Suplatast was given orally ...’.

Furthermore, page 449, right-hand column, lines 1 and 2 should read: ‘... by oral administration of suplatast (100 mg/kg) 1 h prior to antigen challenge. In contrast, as shown in Fig. 2, ...’.

The Authors

* Corresponding author. Tel.: (81-429) 72-8900; Fax: (81-429) 72-8913.

¹ PII of original article: S0014-2999(96)00810-2.